Humanin: the mitochondrial DNA peptide

Humanin is a 21-amino-acid peptide encoded in human mitochondrial DNA, specifically within the 16S ribosomal RNA region. It was first described in 2001 by Ikuo Nishimoto's laboratory in Tokyo, in a paper published in *Proceedings of the National Academy of Sciences*: the team identified a molecule that blocked neuronal death induced by genes linked to familial Alzheimer's disease and by the amyloid beta peptide (Aβ). Unlike most molecules studied in cell biology, humanin is transcribed not from nuclear DNA but from the mitochondrial genome, making it the first member of what is now called the mitochondria-derived peptide (MDP) family.

A peptide from the mitochondria

The mitochondrion carries its own genome: circular, roughly 16,500 base pairs, maternally inherited. Most of its genes encode components of the respiratory chain. The finding that a fragment of the 16S ribosomal RNA could produce a secreted peptide was unexpected when first published, and it prompted debate about whether translation occurs inside the mitochondrion, in the cytoplasm, or in both compartments.

What the published literature established is that humanin can be released by cells into the extracellular space and act on surface receptors in other cells, behaving as an endocrine or paracrine signal. Receptors identified in the research literature include CXCR4, the gp130/IL-6ST complex — the same receptor that mediates interleukin-6 signaling — and formyl peptide receptor 2 (FPR2). That three distinct receptor systems recognize the same molecule suggests humanin's signaling is integrated across multiple cellular pathways in parallel, rather than through a single linear cascade.

What the scientific literature investigates

Neuroprotection and Alzheimer's disease

The foundational paper by Hashimoto and colleagues (PMID 11344269) showed that humanin protected neurons from cell death induced by seven distinct presenilin 1 mutations, the amyloid precursor protein gene, and the Aβ1-43 peptide in cell cultures. The effect was selective: it did not affect the viability of non-neural cells under the same conditions.

Later experiments extended the finding to mouse models with Alzheimer-like pathology and examined underlying mechanisms. Those with the most accumulated evidence include inhibition of BAX-mediated apoptosis, activation of cell survival pathways through the JAK2/STAT3 and MAPK cascades, and reduction of reactive oxygen species in neurons under oxidative stress. Each mechanism was documented in culture systems or specific animal models; none has clinical validation in humans to date.

Metabolism and pancreatic function

A 2013 review by Lee, Yen, and Cohen in *Trends in Endocrinology & Metabolism* (PMID 23206320) summarized the evidence on humanin in metabolic contexts. Studies reviewed documented effects on insulin sensitivity in animal models of induced resistance, protection of pancreatic beta cells against cytotoxic agents such as streptozotocin, and modulation of hepatic lipid metabolism. The authors framed humanin within a system of mitochondria-to-body communication that was in early stages in 2013 and is now an active research area with multiple groups working in parallel.

Inflammation and oxidative stress

Research in macrophages and endothelial cells documented that humanin reduces the expression of pro-inflammatory mediators including TNF-α and IL-6 under conditions of oxidative stress. Signaling through formyl peptide receptor FPR2 has been proposed as one mediator of that effect, though the complete picture of humanin's anti-inflammatory signaling remains under discussion in the literature.

Aging and longevity

Pinchas Cohen's group at the University of Southern California reported that circulating humanin levels in humans tend to decrease with age, and that offspring of centenarians show significantly higher plasma concentrations than age-matched controls without family histories of exceptional longevity. Those observations are correlational: they measure an association and do not establish whether humanin is a cause, consequence, or marker of that aging profile. The distinction matters, and the literature makes it.

The MDP family: humanin is not alone

Humanin was the first mitochondria-derived peptide identified, but bioinformatic searches of the mitochondrial genome led the same laboratory to describe several additional peptides in the same category. The most studied after humanin is MOTS-c, encoded in the 12S mitochondrial ribosomal RNA. MOTS-c research concentrates on glucose metabolism regulation in skeletal muscle and intracellular signaling under energy restriction, distinguishing it from humanin both in its coding location and in the biological contexts most examined.

The existence of this family reshaped how researchers think about the mitochondrion's role in cell biology. The mitochondrion is not only an ATP factory: it is also a source of peptide signals that communicate mitochondrial energy status to the nucleus, cytoplasm, and other cells. That retrograde mitochondrial signaling organizes much of current research in aging biology and metabolism, and humanin was the first experimental evidence that such a system exists. Other compounds investigated in adjacent areas of the longevity and aging literature — including epitalon and NAD+ — are available through the PeptoClinic catalogue.

Current state of research

Most published studies on humanin are in cellular and animal models. Human studies are few and preliminary: some measured plasma humanin levels in specific populations — centenarians, people with type 2 diabetes, individuals with polycystic ovary syndrome — but without controlled clinical trials evaluating humanin intervention in humans. PubMed indexes several hundred publications mentioning humanin since 2001, which reflects sustained scientific interest but does not equal clinical consensus or established translational evidence.

Research use only

PeptoClinic supplies research peptides to laboratories and scientific teams in the United States, Argentina, and other destinations listed on the shipping page. All material is supplied strictly as Research Use Only (RUO): for in vitro and laboratory research exclusively.

Humanin is not a medicine. It is not approved for human or veterinary use by any regulatory authority. PeptoClinic does not prescribe protocols, does not advise on administration, and does not respond to questions about doses or routes of application. Material is accompanied by analytical documentation including the laboratory report and purity specification. The quality page describes what is verified in each lot before dispatch.